PSA Testing: Don't toss the baby out with the bathwater: Readers respond to “Two major studies add fuel to fire of PSA controversy,” April 2009, Cancer Care Practice & Policy, page 8.

Publication
Article
Oncology NEWS Today BlogOncology NEWS Today Blog Vol 18 No 5
Volume 18
Issue 5

PSA is the most important biomarker in a common malignancy. I will continue to test men starting at age 35 if there is a family history of prostate or breast cancer. Depending on the vitality of the individual, I will continue with PSA testing for the duration of the man’s health.

PSA is the most important biomarker in a common malignancy. I will continue to test men starting at age 35 if there is a family history of prostate or breast cancer. Depending on the vitality of the individual, I will continue with PSA testing for the duration of the man’s health.

I have been involved in prostate cancer diagnosis and management as a subspecialty of medical oncology since 1983. With the advent of PSA testing, the world of prostate cancer changed dramatically for the better. Routine use of PSA testing in Qubec province showed a drastic reduction in advanced presentations in prostate cancer (Prostate 59:311-318, 2004). Anyone who manages prostate cancer patients would confirm the clinical value of PSA testing. In patients undergoing PSA screening, or in those undergoing interval PSA testing, advanced presentations of disease are rare. In men diagnosed with prostate cancer based on PSA screening, the decision to perform invasive treatment-and the skill of the physician performing such treatment-is the crux of the matter, not the value of the PSA as a lab test.

We physicians often toss the baby out with the bathwater. Specific criteria for those men best treated after active, objective surveillance have been published in multiple articles by Laurence Klotz, MD, president of the Canadian Urological Association. Other issues involving the skill of physicians performing any form of local therapy have been covered in the literature, but there have been no efforts to quantify the skill of such physicians. We rate consumer products like kitchen appliances, restaurants, and software but not the skill of urologists who do radical prostatectomy or cryosurgery.

When I first started my medical oncology practice in prostate cancer, the majority of my patients who had a radical prostatectomy were grossly incontinent. I identified a very small group of urologists scattered around the country who reported virtually no incontinence related to radical prostatectomy in their patients. I referred my patients to those urologists. As a result, I was not popular among my local community of oncology colleagues, but I was popular with my patients.

Individualization of patient care is an important but missing element in modern medicine. Academia tends toward polarization with statistical analysis. I will not pigeonhole patients and their care based on the findings of studies that average out the pluses and minuses of a test.

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Related Content